Ethynylcytidine

N/A

Report date: 2022/12/07 17:06:28
NME

Base Information

Drug NameEthynylcytidine
Drug Alias NameTAS-106SB-596168ECyd
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsCytidine triphosphate synthetase inhibitorsDNA-directed RNA polymerase II subunit RPB1 inhibitors +[4] 
TargetsCytidine triphosphate synthetaseDNA-directed RNA polymerase II subunit RPB1DNA-directed RNA polymerase I subunit RPA1 +[4] 
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeTaiwan +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTaiho Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTaiho Pharmaceutical Co LtdThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsSolid tumoursHead and Neck NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A